GAITHERSBURG, Md. - FluMist should be used in children between 1 and 5 years old, a majority of FDA advisors recommended Wednesday, supporting MedImmune Inc.'s bid to expand use of the live influenza virus vaccine. (BioWorld Today)

With a deal for its preclinical treatment for tackling dyslipidemia, KB-5359, thought to be imminent, Karo Bio AB strengthened its hand in partnering negotiations by completing a discounted rights offering that grossed SEK406 million (US$59.6 million). The cash is intended to fund the company through 2009 and into 2010. (BioWorld International)